MARKETING RESEARCH OF PHARMACEUTICAL MARKET OF NON-STEROIDAL ANTIINFLAMMATORY DRUGS
DOI:
https://doi.org/10.11603/2312-0967.2016.2.6651Keywords:
market research, non-steroidal anti-infl ammatory drugs, the pharmaceutical market of Ukraine, assortment.Abstract
Introduction. Today nonsteroidal anti-inflammatory drugs (NSAIDs) occupy the leading position in terms of the general population. Thus, worldwide more than 30 million people are forced to take NSAIDs continuously, and 300 million people consume NSAIDs short courses.
According to international and domestic experience NSAIDs are among the most common drugs used for self-medication. One of the conditions for the rational use of NSAIDs by doctors, pharmacists and consumers is to develop the necessary range of these drugs taking into account international trade and generic names, dosage forms, producing countries, as well as purchasing and retail prices, that will provide marketing and economic availability of medicines and satisfy the demand of Ukrainian population.
Based on the above, the purpose of our study was the analysis of the assortment of domestic pharmaceutical market of NSAIDs.
Investigation methods. In order to monitor the state of the pharmaceutical market of NSAID we conducted a marketing research using structural, logical, graphic, system and content analysis of the State Register of medicines’ data. Market analysis conducted in accordance with international non-proprietary names (INN), trade names, dosage form, the country of the manufacturer, and basic pharmacological characteristics.
Results and discussion. According to the data of State Register of medicines we found that in January 2015 the overall nomenclature of registered in Ukraine NSAIDs were 397 trade names of drugs excluding dosage forms. The investigated group presented by 28 INN, among which only 1 INN occured in multicomponent form and 18 INN was mono drugs.
The results of the analysis of medicines registered in Ukraine according to the country of origin found that NSAIDs are supplied to the domestic pharmaceutical market from 39 countries. However, Ukraine has produced only 135 trade names of investigated medicines considering dosage forms, and 262 trade names were represented by foreign manufacturers of NSAIDs. Ratio of NSAIDs’ trade names of domestic and foreign production was 34% s 66% respectively.
The research results of the assortment of NSAIDs by dosage forms demonstrates that studied medicines are presented in nineteen dosage forms, among which tablets make up the largest share - 50.1%, solutions for injections occupy 13.1% of nomenclature, capsules - 10.1%. The smallest measure on market represents caplets, syrups and nasal sprays - 0.3% of the studied group of medicines.
The results of the analysis of the assortment of NSAIDs according to mechanism of action demonstrate that the first group of medicines - selective inhibitors of COX-1 - accounts for 8.3% of all registered trade names.
The largest number of trade names presented in the group of non-selective NSAIDs and includes 301 medications, among which a leading position occupy diclofenac (21.2%), paracetamol (12.6%), ibuprofen (11.8%) and meloxicam (7.8%).
Selective COX-2 inhibitors make up 13.6% of all studied groups of medicines.
Group of highly selective COX-2 inhibitors includes 9 trade names, representing 2.3% of the total market of NSAIDs.
Conclusions. The results of the market research determined that in Ukraine in January 2015 were registered 397 trade names of NSAIDs excluding dosage forms.
The ratio of registered subgroups of the INN according to ATC classification was studied. Has been determined that the largest share of medicines were represented by such groups as diclofenac, ibuprofen and paracetamol, which together make up 45.6% of the studied assortment.
Ratio of trade names of NSAIDs of foreign and domestic production is 66% and 34% respectively, reflecting the general market trends of the pharmaceutical market.
Conducted research showed that the most widespread NSAID dosage forms are tablets, solutions for injections and capsules.
References
McGettigan P., Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries [Electronic resourse] / P. McGettigan, D. Henry // PLoS Med. 2013. – № 10 (2). – Mode of access: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001388.
Teinilä T. Primary care physicians' perceptions of medication errors and error prevention in cooperation with community pharmacists / T. Teinila, K. Kaunisvesi, and M. Airaksinen. // Research in Social and Administrative Pharmacy. – 2011. – № 2. – P. 162–179.
Scanzello C. R. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis / C. R. Scanzello, N. K. Moskowitz, A. Gibofsky. // Current Rheumatology Reports. – 2008. Vol. 10. – № 1. – P. 49–56.
Problemy revmatychnykh zakhvoryuvan' u praktytsi simeynoho likarya. Ranniy diahnoz i likuvannya : navch. posib. / [Zhdan V. M. ta in.] ; Vyshch. derzh. navch. zakl. Ukrayiny «Ukr. med. stomatol. akad.». – Poltava : ASMI, 2013. – 249 s.
European Medicines Agency (2012). Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk: outcome of a procedure under Article 5(3) of Regulation (EC) № 726/20041 [Electronic resourse]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001637.jsp&mid=WC0b01ac058004d5c1.
Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments: pharmaceuticals, fourteenth issue / Department of Economic and Social Affairs of the United Nations Secretariat. – New York, 2009. – 94 p.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
